Alzinova AB (publ) (?Alzinova? or the ?Company?) announced that the Company?s scientific article based on clinical results from ALZ-101 has been accepted for publication in the highly ranked, peer-reviewed journal Alzheimer?s Research & Therapy. The article, titled ?Safety, Tolerability and Immunogenicity of Vaccine ALZ-101 in Patients with, presents the clinical results from the Early Alzheimer?s Disease: Randomised, Controlled Trial?Company?s Phase 1b study of ALZ-101, a therapeutic vaccine candidate targeting toxic amyloid-beta oligomers.

It includes an in-depth analysis of study data, covering both primary and secondary endpoints as well as a number of exploratory endpoints highlighting the potential disease-modifying effects of ALZ-101. The results demonstrate a favorable safety and tolerability profile along with the induction of a specific immune response, which collectively supports the continued clinical development of ALZ-101. The publication provides external validation of the quality of the Company?s clinical data and strengthens the scientific foundation of ALZ-101 at a stage where Alzinova is actively preparing for the next phase of development.

Visibility in an international scientific journal also contributes to increasing interest from the global research community and provides tangible support in the Company?s ongoing partnering discussions. Supported by the positive clinical results, Alzinova is now intensifying preparations for the next stage of development. The Company is planning a Phase II study focused on further evaluating clinical efficacy, biomarkers, and dosing regimen in patients with early Alzheimer?s disease, with the ambition to initiate the study around the turn of the year.

In parallel, dialogues with potential partners are ongoing ahead of the next phase of development. The article will be published open access following the journal?s standard production process. The publication is expected to further increase the international visibility of ALZ-101 and serve as an important foundation for the Company?s continued clinical and business development.